Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
- PMID: 29673325
- PMCID: PMC5909254
- DOI: 10.1186/s12885-018-4371-0
Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
Abstract
Background: To identify the incidence, recurrence pattern and prognosis of brain metastases (BM) among women with metastatic triple negative breast cancer (mTNBC) treated consecutively at a single institution during a 7-year period.
Methods: Patients with histologically confirmed mTNBC were retrospectively identified. The incidence of BM as first site of recurrence and the cumulative BM incidence were computed. We used the Cox proportional hazards model to identify the univariate and multivariate factors associated with survival.
Results: Four hundred thirty three patients were included with a median overall survival (OS) of 21.6 months after median follow-up for 48.1 months. BM was found in 29% (127/433) of the patients and about a quarter (32/127) of BM was first recurrence. The cumulative incidence of BM at 1 and 2 years was 17 and 25%, respectively. The median time from the diagnosis of extracranial metastases to BM was 10 months. Median OS following a diagnosis of BM was 7.3 months. The longer median OS from time of first recurrent BM was noted compared with those of subsequent recurrent (17.3 vs 6.3 months, p = 0.008). However, patients with first recurrent BM were associated with shorter OS compared with those without BM (17.3 vs 22.1 months, p = 0.006). The independent factors that increased BM death risk were > 3 brain lesions, no BM-directed treatment, subsequent recurrent BM, symptomatic BM and uncontrolled extracranial metastasis.
Conclusions: Patients with mTNBC have a high incidence of early BM with subsequent poor survival. The findings lend support to consideration of screening imaging of the brain for mTNBC patients.
Keywords: Brain metastases; Prognosis; Recurrence pattern; Triple-negative breast cancer.
Conflict of interest statement
Ethics approval and consent to participate
This study was conducted inaccordance with the ethical standards of the Declaration of Helsinki and was approved by the Ethics Committee of Fudan University Shanghai Cancer Center. Written human subject consent was not necessary, because this study was based on the retrospective chart review. The institution review board of Fudan University Shanghai Cancer Center approved the waiver.
Competing interests
The authors declare that they have no competing interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures

Similar articles
-
[Survival of Patients with Metastatic Recurrent Triple-negative Breast Cancer].Sichuan Da Xue Xue Bao Yi Xue Ban. 2016 Jul;47(4):541-546. Sichuan Da Xue Xue Bao Yi Xue Ban. 2016. PMID: 28591958 Chinese.
-
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer.Cancer. 2012 Oct 1;118(19):4652-9. doi: 10.1002/cncr.27434. Epub 2012 Feb 22. Cancer. 2012. PMID: 22359359 Free PMC article.
-
Clinicopathological features and prognostic evaluation of bone metastasis in triple-negative breast cancer.J Cancer Res Ther. 2017;13(5):778-784. doi: 10.4103/jcrt.JCRT_543_17. J Cancer Res Ther. 2017. PMID: 29237903
-
Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.Breast Cancer Res. 2019 Dec 16;21(1):143. doi: 10.1186/s13058-019-1210-4. Breast Cancer Res. 2019. PMID: 31842957 Free PMC article.
-
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.Neuro Oncol. 2021 Jun 1;23(6):894-904. doi: 10.1093/neuonc/noaa285. Neuro Oncol. 2021. PMID: 33367836 Free PMC article.
Cited by
-
Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective.Breast Cancer (Dove Med Press). 2022 Jan 10;14:1-13. doi: 10.2147/BCTT.S274514. eCollection 2022. Breast Cancer (Dove Med Press). 2022. PMID: 35046721 Free PMC article. Review.
-
The role of the immune system in brain metastasis.Curr Neurobiol. 2019 Jul;10(2):33-48. Curr Neurobiol. 2019. PMID: 31097897 Free PMC article.
-
Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.Neurosurgery. 2020 Sep 1;87(3):E281-E288. doi: 10.1093/neuros/nyaa095. Neurosurgery. 2020. PMID: 32302389 Free PMC article. Review.
-
Use of Natural Language Processing to Infer Sites of Metastatic Disease From Radiology Reports at Scale.JCO Clin Cancer Inform. 2024 May;8:e2300122. doi: 10.1200/CCI.23.00122. JCO Clin Cancer Inform. 2024. PMID: 38788166 Free PMC article.
-
Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial.Nat Commun. 2024 Aug 7;15(1):6707. doi: 10.1038/s41467-024-50558-9. Nat Commun. 2024. PMID: 39112464 Free PMC article. Clinical Trial.
References
-
- Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, Alexander BM, Lin NU, Aizer AA. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 2017;3(8):1069–1077. doi: 10.1001/jamaoncol.2017.0001. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical